Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ApexOnco Front Page
Recent articles
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
MK-8294 starts phase 1, but its mechanism is anybody's guess.
A single but durable stable disease sends the microcap's stock up 730%.
A newly published cache of CRLs includes six novel oncology drugs.
